March 17, 2020 / 10:54 PM / 15 days ago

BRIEF-Cansino Biologics Says Recombinant Novel Coronavirus Disease Vaccine Approved For Trial

March 18 (Reuters) - Cansino Biologics Inc:

* RECOMBINANT NOVEL CORONAVIRUS DISEASE VACCINE (ADENOVIRUS TYPE 5 VECTOR) APPROVED FOR CLINICAL TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below